Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emil J Freireich

Showing results (31-40 of 59) with videos related to

Pageof 6
Sort By:
Anticancer Research|July 4, 2012
The organic arsenic derivative GMZ27 induces PML-RARα-independent apoptosis in myeloid leukemia cellsXiaodong Cheng, Alfonso Quintás-Cardama, Mirna Golemovic, et al.
Cancer|April 30, 2005
Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986Rashid Saba, Elias Jabbour, Francis Giles, et al.
Blood|August 4, 2007
Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemiaEhab Atallah, Jorge Cortes, Susan O'Brien, et al.
Cancer|September 19, 2008
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 yearsHagop Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Cancer Chemotherapy and Pharmacology|May 9, 2003
In vitro activity of dimethylarsinic acid against human leukemia and multiple myeloma cell linesHatice Duzkale, Iman Jilani, Nada Orsolic, et al.
Investigational New Drugs|May 27, 2009
MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cellsMirna Golemovic, Alfonso Quintás-Cardama, Taghi Manshouri, et al.
American Journal of Hematology|February 27, 2026
The Care and Cure of the Leukemias in 2026Hagop Kantarjian, Helen T Chifotides, Fadi G Haddad, et al.
Cancer|May 10, 2012
Clinical and proteomic characterization of acute myeloid leukemia with mutated RASTapan M Kadia, Hagop Kantarjian, Steven Kornblau, et al.
Cancer|July 16, 2008
Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemiaApostolia-Maria Tsimberidou, Hagop M Kantarjian, Sijin Wen, et al.
Haematologica|August 10, 2012
Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignanciesGautam Borthakur, Michael G Rosenblum, Moshe Talpaz, et al.
Pageof 6

Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
Anticancer Research|July 4, 2012
The organic arsenic derivative GMZ27 induces PML-RARα-independent apoptosis in myeloid leukemia cellsXiaodong Cheng, Alfonso Quintás-Cardama, Mirna Golemovic, et al.
Cancer|April 30, 2005
Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986Rashid Saba, Elias Jabbour, Francis Giles, et al.
Blood|August 4, 2007
Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemiaEhab Atallah, Jorge Cortes, Susan O'Brien, et al.
Cancer|September 19, 2008
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 yearsHagop Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Cancer Chemotherapy and Pharmacology|May 9, 2003
In vitro activity of dimethylarsinic acid against human leukemia and multiple myeloma cell linesHatice Duzkale, Iman Jilani, Nada Orsolic, et al.
Investigational New Drugs|May 27, 2009
MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cellsMirna Golemovic, Alfonso Quintás-Cardama, Taghi Manshouri, et al.
American Journal of Hematology|February 27, 2026
The Care and Cure of the Leukemias in 2026Hagop Kantarjian, Helen T Chifotides, Fadi G Haddad, et al.
Cancer|May 10, 2012
Clinical and proteomic characterization of acute myeloid leukemia with mutated RASTapan M Kadia, Hagop Kantarjian, Steven Kornblau, et al.
Cancer|July 16, 2008
Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemiaApostolia-Maria Tsimberidou, Hagop M Kantarjian, Sijin Wen, et al.
Haematologica|August 10, 2012
Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignanciesGautam Borthakur, Michael G Rosenblum, Moshe Talpaz, et al.
Pageof 6